Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Oak Valley Bancorp | OVLY | Oct 31, 2024 | 27.00 | -0.18 |
Oak Woods Acquisition | OAKU | Oct 31, 2024 | 11.21 | +0.09 |
Oaktree Acquisition III Life Sciences Unit | OACCU | Oct 31, 2024 | 10.00 | 0.00 |
Oaktree Capital A Pref | OAK-A | Oct 31, 2024 | 24.42 | +0.33 |
Oaktree Capital Group B Pref | OAK-B | Oct 31, 2024 | 23.55 | +0.51 |
Oaktree Specialty | OCSL | Oct 31, 2024 | 16.22 | -1.04 |
Oatly ADR | OTLY | Oct 31, 2024 | 0.82 | +2.27 |
Oblong | OBLG | Oct 31, 2024 | 3.55 | +0.85 |
Occidental Petroleum | OXY | Oct 31, 2024 | 50.11 | -0.12 |
Ocean Biomedical | OCEA | Oct 31, 2024 | 0.88 | +0.80 |
Ocean Power Technologies | OPTT | Oct 31, 2024 | 0.15 | +0.54 |
Oceaneering International | OII | Oct 31, 2024 | 24.40 | -1.37 |
OceanFirst Financial | OCFC | Oct 31, 2024 | 18.20 | -1.83 |
OceanFirst Pref | OCFCP | Oct 31, 2024 | 24.95 | -2.19 |
OceanPal | OP | Oct 31, 2024 | 1.61 | -1.55 |
Ocugen | OCGN | Oct 31, 2024 | 0.91 | -6.47 |
Ocular Therapeutix | OCUL | Oct 31, 2024 | 10.53 | -4.96 |
Oculis | OCS | Oct 31, 2024 | 17.18 | +0.06 |
Ocuphire Pharma | OCUP | Oct 31, 2024 | 1.17 | 0.00 |
Ocuphire Pharma | IRD | Oct 31, 2024 | 1.20 | 0.00 |
Oddity Tech | ODD | Oct 31, 2024 | 38.39 | -2.17 |
Odyssey Marine Exploration | OMEX | Oct 31, 2024 | 0.52 | +0.52 |
Offerpad Solutions A | OPAD | Oct 31, 2024 | 3.01 | +0.33 |
Office Properties | OPI | Oct 31, 2024 | 1.59 | -19.29 |
OFG Bancorp | OFG | Oct 31, 2024 | 40.27 | -1.30 |
OFS Capital | OFS | Oct 31, 2024 | 8.10 | -0.61 |
OFS Credit | OCCI | Oct 31, 2024 | 7.07 | +0.57 |
OFS Credit C Pref | OCCIO | Oct 31, 2024 | 24.63 | -0.69 |
OFS Credit Company Pref F | OCCIM | Oct 31, 2024 | 24.94 | 0.00 |
OFS Credit E Pref | OCCIN | Oct 31, 2024 | 23.85 | +0.55 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.